There may be two distinct subtypes of multiple sclerosis, according to a new study led by scientists at University College ...

The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

The drug, tolebrutinib, delayed disability progression by 31% in people with a type of MS called non-relapsing secondary progressive multiple sclerosis, researchers reported in the New England Journal ...

Researchers from Kyushu University have identified a potential therapeutic target for the treatment of advanced multiple sclerosis (MS), a potentially disabling condition associated with the central ...

Using advanced methodology, scientists have been able to reveal at the cellular level how lesions in multiple sclerosis develop. Using advanced methodology, scientists in Sweden were able to reveal at ...

(Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in a ...

Differences in the complexity of the EEG signal (yellow and red colors) in a specific brain area between the group with advanced multiple sclerosis and the control group, and multifractal spectra ...

Journals Flag Concerns in 36 Papers by Nutrition Researchers Journals have flagged more than 36 articles by a team of authors in Iran for concern over the integrity of their data since questions were ...

AUGS Overactive Bladder Symptoms in Patients With Multiple Sclerosis Patients with multiple sclerosis have significant rates of overactive bladder symptoms, yet they are not being evaluated or treated ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...